• 01/14/2025, Sophia Antipolis, France

    Financial Communications Schedule for the First Half of 2025

    Median Technologies announces the publication date for its 2024 results.
    Read more Download 20250114_PR_H1financialcom_EN.pdf
  • 01/09/2025, Sophia Antipolis, France

    Half year Median Technologies liquidity contract statement

    Under the liquidity contract entrusted by Median Technologies to TP ICAP (Europe), the following resources were listed in the liquidity account as of December 31, 2024: 30,599 shares, €134,615.99 in cash.
    Read more Download 20250109_PR_liquiditycontHY22024_EN.pdf
  • 01/08/2025, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of December 31st, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of December 31st, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20250108_PR_shares_votingrights_Dec2024.pdf
  • 12/11/2024, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of November 30th, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of November 30th, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20241211_PR_shares_votingrights_Nov2024.pdf
  • 11/26/2024, Sophia Antipolis, France

    Median Technologies to showcase AI-powered lung cancer diagnostic eyonis™ LCS at the Radiological Society of North America (RSNA) 2024

    The Company will share the latest developments for eyonis™ Lung Cancer Screening (LCS) Software as a Medical Device (SaMD) as well as the most recent advances for iCRO central and AI-powered oncology trial imaging services for pharmaceutical companies.
    Read more Download 20241126_PR_RSNA2024_EN.pdf
  • 11/12/2024, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of October 31st, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of October 31st, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20241112_PR_shares_votingrights_october2024.pdf
  • 11/07/2024, Sophia Antipolis, France

    Median Technologies hosted insightful Key Opinion Leader (KOL) webinar on eyonis™ Lung Cancer Screening (LCS) REALITY data

    Two leading U.S. pulmonology experts Prof. Anil Vachani, and Prof. Javier Zulueta, provided their views on the data from REALITY, Median’s recently completed pivotal study of the eyonis™ LCS SaMD, and how the AI powered device may impact lung cancer diagnostics and treatment.
    Read more Download 20241107_PR_PostKOLwebinar_EN.pdf
  • 10/30/2024, Sophia Antipolis, France

    Median Technologies to host Key Opinion Leader (KOL) webinar on AI and lung cancer screening

    Median Technologies will host on November 7, 2024 at 1:30 pm CET / 7:30 am ET a KOL webinar to discuss REALITY, the recently completed study of the eyonis™ LCS SaMD for early diagnosis of lung cancer.
    Read more Download 20241030_PR_KOL_Webinar_EN-1.pdf
  • 10/24/2024, Sophia Antipolis, France

    Median Technologies Reports 2024 Q3 Operational and Financial Update and 2024 Half-Year Results

    Median Technologies announces today that its Board of Directors approved the consolidated IFRS financial statements for the first half of 2024 on October 23, 2024, and provides operational and financial updates from the third quarter of 2024.
    Read more Download 20241024_PR_H120234Q32024_final_EN.pdf
  • 10/07/2024,

    Disclosure of total number of voting rights and number of shares in the capital as of September 30th, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of September 30th, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20241007_PR_shares_votingrights_September2024.pdf
    • 1 … 39